Form 4: Cardiff Oncology CFO Receives Large Stock Option Grant

Cardiff Oncology CFO Joshua Muntner was granted 486,650 stock options as part of an equity compensation package.

Summary

• Joshua Muntner, Chief Financial Officer of Cardiff Oncology, Inc. (CRDF), was granted 486,650 stock options.
• The options have an exercise price of $1.58 per share.
• The grant date is April 6, 2026, with an expiration date of April 6, 2036.
• Vesting schedule: 121,663 options vest on April 6, 2027, with the remaining balance vesting in 36 equal monthly installments thereafter.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard executive compensation practices rather than a change in company fundamentals.

Positives

• Equity-based compensation aligns the interests of the CFO with long-term shareholder value creation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is highly dependent on the future market performance of CRDF common stock.

Future Outlook

The filing does not provide forward-looking business guidance, as it is a standard disclosure of executive equity compensation.

Industry Context

StockSavvy.ai notes that equity grants for C-suite executives in the biotechnology sector are standard practice to incentivize long-term retention and performance, particularly in companies focused on clinical-stage drug development.

Comparison to Industry Standards

• The use of a 4-year vesting schedule (1-year cliff followed by monthly vesting) is consistent with standard corporate governance practices for executive compensation in the U.S. biotech industry.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of the first tranche of options on April 6, 2027.

Key Dates

Keywords

Cardiff Oncology, CRDF, Form 4, Insider Trading, Stock Options, Executive Compensation